Erratum

This article refers to:

Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy

In the article “Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy”, published in the April 2009 issue of Expert Opinion on Biological Therapy (Expert Opin Biol Ther 2009;9(4):451-64), there is an error in Figure 3D. The colours have been incorrectly edited (colours in the legend have been reversed and the bars indicating data for day 19 have been coloured incorrectly). This results in the graph giving misleading information. The corrected figure is shown below.

Figure 3. Delayed B16 tumor kinetics in animals intratumorally injected with biodegradable particles encapsulating IL-2. A. poly(lactide-co-glycolide) (PLGA) particles surface modified with anti-CD3 and anti-CD28 and encapsulating IL-2 (described previously in [54]). B. Experimental timeline. Mice received injections of 1 × 10⁵ B16-luciferase cells (Caliper Life Sciences, Hopkinton, MA) subcutaneously on day 0, treated with PLGA microparticles on day 10, and were killed when tumors reached 2 cm². C. Day 10 tumors imaged using Xenogen IVIS-200 (Caliper Life Sciences) following injection of d-Luciferin. Bioluminescence from the tumors (flux) expressed as photons/second/cm²/steridian (photons/sec/cm²/ster). ROI: region of interest, quantified using Living Image Software (Xenogen, Alameda, CA) and analyzed using Igor Pro Image Software (Wavemetrics, Portland, OR). D. Day 10 tumors were treated with a single intratumoral injection of 2 mg of 8 ± 2 μm PLGA particles. Tumor areas were calculated by taking the product of the cross perpendicular diameters which were obtained using tumor calipers. Control particles did not display antibodies or release cytokine. n = 3 (*, ‡, § indicate a 2-way ANOVA with p values of < 0.001, < 0.01, < 0.05, respectively). Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).

Informa Healthcare would like to apologise for any confusion caused.